4-[2-(4-Bromophenoxy)ethyl]morpholine, 97.0%, 25g

FLEROXACIN, 95%, 1g

Methyl 5-bromo-2,4-dimethylbenzoate, 95.0%, 100mg

Pyr3, 99.90%, 25mg

5'-CHLORO-1,1':3',1''-TERPHENYL, 95%, 250mg

3-(4-Chlorophenoxy)-1,2-propanediol, 99.0%, 10g

Recipiente de cristalización ROTILABO® sin pico, 300 ml, 95 mm, 10 Unidad(es)

Methyl 3-fluoro-4-hydroxybenzoate, 95.0%, 100g

1,2:3,4-DI-O-ISOPROPYLIDENE--D-GALACTOPYRANOSE, 95.0%, 100g

5,7-Dimethoxychroman-4-one, 95.0%, 250mg

3,6-Diphenyl-1,2,4,5-tetrazine>98.0%(qNMR)5g

1-Hydroxyanthracene-9,10-dione, 95.0%, 1g

Objetivo Plan acromático PLM 5x/0,14 LWD IOS. Distancia de trabajo 10,8 mm. Sin corrección de cubreobjetos